Melvin Feifer

Array ( [id] => 18333601 [patent_doc_number] => 20230125549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => METHODS AND COMPOSITIONS FOR ASSESSING IMMUNE RESPONSE IN MURINE TUMOR MODELS [patent_app_type] => utility [patent_app_number] => 18/074532 [patent_app_country] => US [patent_app_date] => 2022-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18074532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451525 [patent_doc_number] => 20230192803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTI-STEAP2 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/046728 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -155 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709201 [patent_doc_number] => 20230331813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS [patent_app_type] => utility [patent_app_number] => 17/965593 [patent_app_country] => US [patent_app_date] => 2022-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17965593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451541 [patent_doc_number] => 20230192819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => SINGLE DOMAIN ANTIBODIES FOR SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 17/820541 [patent_app_country] => US [patent_app_date] => 2022-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389466 [patent_doc_number] => 20240279336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/291271 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18291271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586431 [patent_doc_number] => 20240383988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => ANTIBODIES AGAINST EGFR AND THEIR USES [patent_app_type] => utility [patent_app_number] => 18/573339 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403639 [patent_doc_number] => 20240287150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => METHODS AND COMPOSITIONS RELATING TO TISSUE-PROTECTIVE ERYTHROPOIETIN [patent_app_type] => utility [patent_app_number] => 18/572549 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20645838 [patent_doc_number] => 12600774 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof [patent_app_type] => utility [patent_app_number] => 18/262987 [patent_app_country] => US [patent_app_date] => 2022-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 7658 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 271 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300017 [patent_doc_number] => 20240228586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/559180 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720491 [patent_doc_number] => 20220213211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/693060 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19431043 [patent_doc_number] => 20240299541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL DELIVERY OF ORTHOGONAL IL-2 [patent_app_type] => utility [patent_app_number] => 18/549503 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003687 [patent_doc_number] => 20240067758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => MULTI-SPECIFIC ANTIBODIES AND ANTIBODY COMBINATIONS [patent_app_type] => utility [patent_app_number] => 18/255213 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20248119 [patent_doc_number] => 20250296988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 18/255920 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895493 [patent_doc_number] => 20240010978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => METHOD FOR PREPARING DENDRITIC CELL USING PLATELET LYSATE [patent_app_type] => utility [patent_app_number] => 18/035123 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14565 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955201 [patent_doc_number] => 20240043528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => NANOBODY-OGA FUSIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/030245 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497424 [patent_doc_number] => 20230220058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => Anti-S100A4 antibodies for the treatment of systemic sclerosis [patent_app_type] => utility [patent_app_number] => 18/009821 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657733 [patent_doc_number] => 20230303685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/923778 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067287 [patent_doc_number] => 20210269502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 17/165119 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20744056 [patent_doc_number] => 12643947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-02 [patent_title] => Anti-ROR-2 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/777591 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 22 [patent_no_of_words] => 47073 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097825 [patent_doc_number] => 20240117053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => CLEC12A ANTIBODY FRAGMENT SEQUENCES AND METHODS [patent_app_type] => utility [patent_app_number] => 17/768793 [patent_app_country] => US [patent_app_date] => 2020-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768793 [rel_patent_id] =>[rel_patent_doc_number] =>)